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ABSTRACT
Regulatory t cells (tregs) are key players of immune regulation/dysregulation 
both in physiological and pathophysiological settings. Despite significant advances in 
understanding Treg function, there is still a pressing need to define reliable and specific 
markers that can distinguish different Treg subpopulations. Herein we show for the first 
time that markers of activated tregs [latency associated peptide (LAP) and glycoprotein 
A repetitions predominant (GARP, or LRRC32)] are expressed on CD4+FoxP3− t cells 
expressing Helios (FoxP3−Helios+) in the steady state. Following tCR activation, GARP/LAP 
are up-regulated on CD4+Helios+ t cells regardless of FoxP3 expression (FoxP3+/−Helios+). 
We show that CD4+GARP+/−LAP+ tregs make IL-10 immunosuppressive cytokine but not 
IFN-γ effector cytokine. Further characterization of FoxP3/Helios subpopulations showed 
that FoxP3+Helios+ tregs proliferate in vitro significantly less than FoxP3+Helios− tregs 
upon tCR stimulation. Unlike FoxP3+Helios− tregs, FoxP3+Helios+ tregs secrete IL-10 
but not IFN-γ or IL-2, confirming they are bona fide Tregs with immunosuppressive 
characteristics. taken together, Helios, and not FoxP3, is the marker of activated tregs 
expressing GARP/LAP, and FoxP3+Helios+ tregs have more suppressive characteristics, 
compared with FoxP3+Helios− tregs. Our work implies that therapeutic modalities for 
treating autoimmune and inflammatory diseases, allergies and graft rejection should be 
designed to induce and/or expand FoxP3+Helios+ tregs, while therapies against cancers 
or infectious diseases should avoid such expansion/induction.
INTRODUCTION
Regulatory T cells (Tregs) are immunosuppressive 
cells that regulate function of the immune system. They 
are key in maintaining peripheral immune tolerance. 
Tregs have defined roles in various pathological settings 
including cancer, autoimmune diseases and transplant 
rejection, where they contribute to disease progression 
[1, 2]. Given their role in immune modulation under 
pathological conditions, Tregs have increasingly been 
targeted for novel immunotherapies with some promising 
results in clinical trials [3, 4]. Current approaches include 
Treg depletion and functional blockade to enhance 
immune responses or autologous transfer of Tregs to 
dampen immune responses in certain scenarios [3–5].
Tregs are broadly divided into thymic-derived Tregs 
(tTregs) and peripheral-induced Tregs (pTregs). Both of 
these Treg subsets were originally defined as expressing 
the forkhead box P3 transcription factor (FoxP3) and the 
alpha chain of the IL-2 receptor (CD25). FoxP3 is crucial 
for development and maintenance of the suppressive Treg 
lineage [2]. pTregs comprise two further FoxP3− subsets; 
IL-10 secreting Type 1 Tregs (Tr1) and T helper 3 Tregs 
(Th3) [6, 7]. Recent years have seen significant efforts into 
characterizing Treg markers for effective identification 
and isolation of Treg subsets [2, 5]. The expression of 
FoxP3, CD25 or the ‘immune checkpoint’ molecules 
proposed to identify Tregs, can also define non-regulatory 
T cells (Tconv) and effector T cells (Teff) [5, 8]. CD25 is 
a well-recognized T cell activation marker. The immune 
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checkpoint molecules, CTLA-4, PD-1, LAG-3 and TIM-3, 
can also be up-regulated on activated Tconv and Teff [5]. 
Neuropilin 1 (NRP1), a promising Treg surface marker, 
is also up-regulated during inflammation in vivo [9, 10]. 
FoxP3 can be transiently expressed in T cells undergoing 
activation or in inflammatory microenvironments [11, 12].
We have recently reviewed current Treg markers 
[5]. Of particular interest are two molecules involved 
in the expression and activation of transforming growth 
factor-beta (TGF-β) that selectively identify activated 
Tregs: glycoprotein A repetitions predominant (GARP/
LRRC32) and latency-associated peptide (LAP). LAP and 
TGF-β form inactive complexes on the surfaces of T cells, 
known as latent TGF-β complexes. These complexes can 
be cleaved to release active TGF-β. GARP plays a critical 
role in the formation and expression of latent TGF-β 
complexes at the cell surface by anchoring the complexes 
to the cell membrane [13, 14].
GARP is a transmembrane protein that has been 
identified on activated Tregs, megakaryocytes and platelets 
[13, 15, 16]. GARP forms a positive-feedback loop with 
FoxP3 where expression of one enhances expression of the 
other [16, 17]. Retroviral expression of GARP on human 
T helper (Th) cells with TCR stimulation results in stable 
re-programming of Th cells into functionally suppressive 
FoxP3-expressing Tregs [16, 18]. Down-regulation or 
silencing of GARP on FoxP3+ Tregs decreases both 
FoxP3 expression and suppressive activity [16, 18]. 
Induction of GARP on naïve human T cells also induced 
partial Treg functionality in vitro [19]. GARP itself might 
contribute directly to immune suppression as shown in a 
humanized mouse model where treatment with soluble 
GARP (sGARP) prevented lethal graft-versus-host disease 
(GVHD) following xenogeneic tissue transplantation [20]. 
sGARP also induced development of naïve CD4+ human 
T cells into Tregs in vitro [20].
LAP is up-regulated on activated Tregs and has been 
characterized on megakaryocytes and immature dendritic 
cells (DCs) [21]. LAP has been utilized in conjunction 
with the IL-1 receptors Type I/II (CD121a/b) for 
identification and isolation of functional FoxP3+ human 
Tregs [22]. Highly suppressive FoxP3−LAP+ Tregs have 
also been identified in humans [23]. LAP was recently 
used to effectively identify and isolate functional Tregs 
from patients following immunotherapy with anti-CTLA-4 
antibody [24].
Another marker that has been the focus of 
significant research is the Ikaros zinc finger transcription 
factor, Helios. It was first identified as a selective 
tTreg marker in mice [25]. However, in humans, 
Helios has been characterized in pTregs, tTregs, CD8+ 
T cells, activated T cells and T cells in inflammatory 
microenvironments [5, 26]. Helios has been implicated 
in Treg development and stability by repressing the IL-2 
gene promoter [27, 28]. Helios+ Tregs have been shown 
to exhibit superior suppressive activity, compared to 
Helios− Tregs in mice [29]. In human Tregs, Helios has 
been reported to enhance FoxP3 expression by binding 
the FoxP3 promoter [30]. Helios knockdown impaired the 
suppressive activity and down regulated FoxP3 expression 
[30]. While the exact role of Helios is uncertain, it is 
acceptable that Helios defines a highly suppressive Treg 
subset with distinct phenotypic and functional features 
[31–33]. FoxP3+Helios+ Tregs are significantly expanded 
in circulation and tumor microenvironment in various 
cancers including colorectal cancer, renal cell carcinoma 
and glioblastoma [34–37].
The correlation of FoxP3 and Helios with GARP 
and LAP has not been studied previously. Only one 
study reported that GARP did not correlate with Helios 
expression in CD4+ or in CD4+FoxP3+ cells [26]. LAP 
expression was not investigated. In this study, we 
investigated the co-expression of GARP and LAP with 
FoxP3 and Helios on T cells isolated from the peripheral 
blood of healthy donors. Herein, we show for the first 
time that markers of activated Tregs, GARP/LAP, are 
mainly expressed on FoxP3+Helios+ Tregs, but not on 
FoxP3+Helios− Tregs. Additionally GARP and LAP 
are expressed on a FoxP3−Helios+ subset, indicating 
that Helios, but not FoxP3, is the marker of activated 
Tregs expressing GARP/LAP. We also report that 
FoxP3+Helios+ Tregs exhibit more immunosuppressive 
characteristics compared to FoxP3+Helios− Tregs, 
further supporting the role of Helios as a marker of 
suppressive Tregs.
RESULTS
GARP/LAP are not expressed on FoxP3+ Tregs 
in steady state
We investigated co-expression of different key 
Treg markers including FoxP3 and Helios, as master Treg 
transcription factors, and LAP and GARP, as markers of 
activated Tregs. In steady-state non-activated T cells from 
healthy donors, we noticed that LAP and GARP were not 
co-expressed with FoxP3 on CD4+ Tregs, and low levels 
(<1%) of LAP+ or GARP+ cells were detected in CD4+ 
T cells lacking FoxP3 expression (Figure 1A). This is 
consistent with a recent observation in patients with acute 
coronary syndrome [38].
GARP/LAP are expressed on a subset of 
CD4+FoxP3−Helios+ in non-activated setting
To further define Treg subpopulations and 
investigate GARP/LAP co-expression, we combined 
FoxP3 and Helios staining and analyzed the co-
expression of GARP/LAP on these different subsets. 
When CD4+Helios+ T cells were gated, we found that 
some cells within this subset express GARP/LAP. Of 
note, a significant percentage of CD3+CD4− (CD8+) T cells 
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expresses Helios but unlike CD4+Helios+ T cells, there is 
no GARP/LAP expressed on CD8+ T cells (not shown).
Different FoxP3+/−Helios+/− CD4+ T cell subsets were 
gated, as shown in Figure 1B (first plot). GARP/LAP were 
expressed at negligible levels on non-activated CD4+FoxP3+ 
Tregs, regardless of Helios expression (Figure 1B, last two 
plots). Interestingly, the only subpopulation that expressed 
significantly higher levels of GARP/LAP (4.7 ± 0.8%), 
compared with other subpopulations, was CD4+FoxP3−Helios+ 
in non-activated setting (Figure 1B & 1C).
GARP/LAP are expressed on Helios+, regardless 
of FoxP3 expression, in activated CD4+ T cells
We then investigated GARP/LAP expression 
on FoxP3/Helios CD4+ T cell subsets following TCR 
stimulation for 18–20 hours. Different FoxP3+/−Helios+/− 
CD4+ T cell subsets were gated, as shown in Figure 2A 
(first plot). As expected, GARP/LAP were expressed at 
much higher levels on activated CD4+ T cells, compared 
with non-activated CD4+ T cells (Figures 1B & 2A). Figure 
2A & 2B show the percentages of CD4+ T cells expressing 
GARP/LAP and the Mean Fluorescence Intensities (MFIs) 
of GARP and LAP expression within the different subsets. 
Interestingly, GARP/LAP were mainly expressed on 
FoxP3+Helios+ (26.1 ± 3.8%) and FoxP3−Helios+ (13.7 ± 
3.2%) and to a significantly lower level on FoxP3+Helios− 
(6.5 ± 0.9%), but not on FoxP3−Helios− (0.4 ± 0.1%) CD4+ 
T cells (Figure 2C).
CD4+ T cells expressing GARP/LAP make IL-10 
but not IFN-γ
We then investigated the nature of cytokines 
released from different subpopulations expressing or 
lacking GARP/LAP. PBMCs were stimulated by anti-
CD3/28 for 18–20 hours to allow induction of GARP/
LAP. We noticed GARP/LAP could not be induced 
Figure 1: Expression of GARP and LAP on different FoxP3+/–Helios+/– non-activated T-cell subsets. Thawed PBMCs isolated 
from healthy donors were stained for CD3, CD4, GARP and LAP surface markers followed by FoxP3 and Helios intracellular staining. 
A. Representative flow cytometric plots showing FoxP3 expression against LAP or GARP, as gated on CD3+CD4+ T cells. B. Representative 
flow cytometric plots showing FoxP3−Helios−, FoxP3−Helios+, FoxP3+Helios+ and FoxP3+Helios− T-cell subsets and the expression of GARP/
LAP within these subsets in non-activated cells. C. Scatter plots show the mean percentage ± SEM of GARP+LAP+ within FoxP3−Helios−, 
FoxP3−Helios+, FoxP3+Helios+ and FoxP3+Helios− T-cell subsets in non-activated PBMCs isolated from 14 healthy donors.
Oncotarget20029www.impactjournals.com/oncotarget
on cell surface if Golgi Plug is added during activation 
period; therefore Golgi Pulg was added for only extra 
4 hours to allow detection of cytokines. GARP−LAP− 
CD4+ T cells made IFN-γ effector cytokine but not IL-10 
immunosuppressive cytokine (Figure 3A). On the other 
hand, GARP+LAP+ and GARP−LAP+ CD4+ T cells made 
IL-10 but not IFN-γ (Figure 3A & 3B). Interestingly, 
GARP+LAP+ cells secreted significantly higher levels 
of IL-10 (41.3 ± 5.4%), compared with GARP−LAP+ 
cells (11.5 ± 3.7%), as shown in Figure 3B. We noticed 
that some CD4+ T cells express higher levels of GARP/
LAP. Of note, when GARPhigh/LAPhigh cells were gated, 
almost all of them secreted IL-10, compared to cells 
expressed GARP/LAP at intermediate level (Figure 3C). 
We further confirmed these findings by performing back 
gating. Figure 3D shows that TCR-stimulated CD4+ T 
cells secrete both IL-10 and IFN-γ. CD4+IL-10+ T cells 
expressed GARP/LAP, while CD4+IFN-γ+ T cells lacked 
the expression of GARP/LAP. CD8+ T cells secreted 
IFN-γ but not IL-10, and GARP/LAP were not expressed 
on IFN-γ+ or IFN-γ− CD8+ T cells (not shown).
FoxP3+Helios+ Tregs make IL-10 while 
FoxP3+Helios− Tregs make IL-10 and 
effector cytokines
To further elucidate the nature of different 
FoxP3+/−Helios+/− T-cell subsets with respect to cytokine 
secretion, we investigated the ability of TCR-stimulated 
PBMCs to release different cytokines including IL-10, 
as an immunosuppressive cytokine, and IFN-γ and IL-2, 
as effector cytokines. Proportions of cytokine-secreting 
Figure 2: Expression of GARP and LAP on different FoxP3+/–Helios+/– T-cell subsets in the activated setting. PBMCs from 
healthy donors were activated by plate-bound anti-CD3/28 followed by surface staining for CD3, CD4, GARP and LAP and intracellular 
staining for FoxP3 and Helios. A. Representative flow cytometric plots showing FoxP3−Helios−, FoxP3−Helios+, FoxP3+Helios+ and 
FoxP3+Helios− T-cell subsets and the expression of GARP/LAP within these subsets in activated PBMCs. B. Representative overlaid 
histogram plots show the MFIs of GARP and LAP within the different FoxP3/Helios subsets. C. Scatter plots show the mean percentage ± 
SEM of GARP+LAP+ within FoxP3−Helios−, FoxP3−Helios+, FoxP3+Helios+ and FoxP3+Helios− T-cell subsets in activated PBMCs isolated 
from 19 healthy donors.
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Figure 3: Intracellular cytokine secretion from different GARP+/–LAP+/– CD4+ T-cell subsets. A. Representative flow 
cytometric plots showing GARP+/−LAP+/− T-cell subsets and cytokine release (IFNγ and IL-10) from these subsets following PBMCs 
activation. B. Mean percentage ± SEM of IL-10-secreting cells within GARP+/−LAP+/− CD4+ T-cell subsets in activated PBMCs isolated 
from 10 healthy donors. C. Flow cytometric plots showing that some CD4+ T cells express higher levels of GARP/LAP, and all GARPhigh/
LAPhigh cells secreted IL-10, compared to GARPinter/LAPinter. The overlaid histogram plot shows that MFI of IL-10 expression is higher 
within GARPhigh/LAPhigh cells (red) than GARPinter/LAPinter cells (blue). D. Representative flow cytometric plots show the secretion of IL-10 
and IFN-γ from CD4+ T cells; IL-10-secreting CD4+ T cells express GARP/LAP, while IFN-γ-secreting CD4+T cells lack the expression 
of GARP/LAP.
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cells were not as high as in previous studies because cells 
were stimulated with anti-CD3/CD28 and not by PMA/
ionomycin to allow induction of GARP/LAP. We found that 
effector cytokines were secreted mainly by FoxP3+Helios− 
Tregs (IFN - γ: 4.7 ± 0.94%; IL - 2: 4.3 ± 1.6%) and 
FoxP3−Helios− conventional CD4+ T cells (IFN-γ: 1.7 ± 
0.94%; IL-2: 4.3 ± 1.6%) (Figure 4). FoxP3+Helios− Tregs 
contained significantly higher proportions of IFN-γ+ cells, 
compared with all other subpopulations (Figure 4C). In 
addition, FoxP3+Helios− Tregs contained some proportions 
of IL-10+ cells (4.5 ± 1.5%, Figure 4E). Secreting a mixture 
of effector and immunosuppressive cytokines could be 
interpreted as FoxP3+Helios− Tregs containing a mixture of 
bona fide Tregs and conventional Teff that were induced 
to express FoxP3 without being real Tregs. On the other 
hand, FoxP3+Helios+ Tregs, the subpopulation expressing 
GARP/LAP in the activated setting (as described in 
Figure 2), contained the highest levels of IL-10+ cells 
(6.4 ± 2.1%, Figure 4E), and did not make IFN-γ or IL-2 
(Figure 4C & 4D, 4E).
FoxP3+Helios+ Tregs have less proliferative 
ability than FoxP3+Helios− Tregs
To get further insights into the nature of different 
FoxP3+/−Helios+/− T-cell subsets, we investigated their 
ability to proliferate in response to TCR stimulation. 
We set up crude proliferation assays in which all cell 
populations in PBMCs were kept. This allows the release 
of IL-2 from TCR-stimulated CD4+ T effector cells that 
can be used by cells expressing the high affinity IL-2R α 
chain (CD25). We found that FoxP3+Helios− CD4+ Tregs 
proliferated significantly higher (59.2 ± 5.4%, Figure 5A 
& 5B) than all other subpopulations, which showed similar 
proliferation levels (32–35%, Figure 5B). Having less 
proliferation capability in response to TCR stimulation 
even in the presence of IL-2 secreted by effector 
cells confirms that FoxP3+Helios+ are more anergic, a 
characteristic of bona fide Tregs. We measured levels 
of CD25 expression before and after TCR stimulation 
to determine the role of IL-2 in inducing proliferation 
Figure 4: Intracellular cytokine secretion from different FoxP3+/–Helios+/– T-cell subsets. Representative flow cytometric 
plots showing FoxP3+/−Helios+/− T-cell subsets and intracellular cytokine secretion of IFNγ and IL-10 (A) and IL-2 (B) from these different 
subsets following PBMCs activation. Mean percentage ± SEM of IFNγ (C. n = 9), IL-2- (D. n = 6) and IL-10-secreting cells (E. n = 8) 
within the different FoxP3+/−Helios+/− CD4+T-cell subsets.
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of different subsets. As expected, without activation 
FoxP3+Helios+ and FoxP3+Helios− Tregs showed 
constitutive expression of significantly higher levels of 
CD25 (75.2 ± 2.3% and 73.7 ± 8.2%, respectively; Figure 
5C), compared with FoxP3−Helios+ and FoxP3−Helios− 
subsets (19.4 ± 3.7% and 17.1 ± 5.3%, respectively; Figure 
5C). Following TCR stimulation, CD25 was induced on 
FoxP3−Helios+ (52.2 ± 15.2%, Figure 5D), FoxP3+Helios− 
(94.8 ± 2.8%, Figure 5D), and FoxP3−Helios− (56.8 ± 
12.0%, Figure 5D), but not on FoxP3+Helios+ Tregs, which 
showed similar levels of CD25 as per before stimulation 
(79.7 ± 8.5%, Figure 5D). The highest expression of CD25 
was detected on FoxP3+Helios− Tregs, confirming their 
higher proliferative capability compared to other subsets. 
Although, FoxP3+Helios+ and FoxP3+Helios− Tregs 
expressed similar levels of CD25 prior to stimulation, 
CD25 was further induced on only FoxP3+Helios− Tregs, 
which proliferated significantly higher.
DISCUSSION
In this study, we investigated the differences 
between FoxP3+/−Helios+/− CD4+ T cell subsets. These 
included GARP/LAP expression, proliferative capacity 
and cytokine secretion. GARP and LAP are promising 
late-stage Treg activation markers that are selectively up-
regulated on activated Tregs but not on Teff. GARP and 
LAP also play functional roles in Treg suppressive activity, 
making them particularly useful as Treg markers in vitro 
and in vivo [13–15, 24]. We here report that, in the steady 
state, GARP and LAP are expressed on FoxP3−Helios+ 
CD4+ T cell subset significantly more than CD4+FoxP3+ 
Tregs, regardless of Helios expression. We also report, for 
the first time, that in the activated setting, GARP and LAP 
are expressed on FoxP3+Helios+ and FoxP3−Helios+ T cell 
subsets. They are expressed at significantly lower levels on 
FoxP3+Helios− CD4+ T cells, and not on FoxP3−Helios− T 
cells. These findings indicate that Helios, and not FoxP3, 
is the key marker to identify activated Tregs, expressing 
GARP and LAP.
We investigated specific cellular characteristics 
associated with suppression within different FoxP3+/− 
Helios+/− T-cell subsets following activation. We 
found that FoxP3+Helios+ Tregs exhibit more 
immunosuppressive characteristics, compared 
with FoxP3+Helios− Tregs. These characteristics 
included expression of GARP/LAP, secretion of 
immunosuppressive IL-10, lack of effector cytokine 
secretion (IFN-γ and IL-2) and lower proliferative 
capacity. FoxP3+Helios+ Tregs contained the highest 
Figure 5: CFSE-based proliferation assays and CD25 expression within different FoxP3+/–Helios+/– T-cell subsets.  
A. Representative flow cytometric plots showing FoxP3−Helios−, FoxP3−Helios+, FoxP3+Helios+ and FoxP3+Helios− T-cell subsets (first 
plot) and their proliferation (second plot) as measured by CFSE loss. B. Mean percentage ± SEM of cell proliferation of these different 
subsets in PBMCs isolated from 9 healthy donors. Flow cytometric plots and mean percentage ± SEM of CD25 expression in non-activated 
(C) and activated (D) FoxP3+/−Helios+/− T-cell subsets in PBMCs isolated from 5 healthy donors.
Oncotarget20033www.impactjournals.com/oncotarget
levels of IL-10+ cells (6.4 ± 2.1%, Figure 4E), and 
did not secrete significant levels of effector cytokines. 
In contrast, FoxP3+Helios− T cells secreted effector 
cytokines, and contained the highest proportions of 
IFN-γ+ cells. This FoxP3+Helios− T cell subset also 
contained IL-10+ cells (4.5 ± 1.5%, Figure 4E) potentially 
indicating a mixture of bona fide Tregs, and Teff 
transiently induced to express FoxP3. The FoxP3+Helios− 
T cell subset has previously been shown to comprise a 
mixture of T cells secreting IL-10, IL-2, IFN-γ and 
IL-17 [33]. They have also been reported to comprise 
a significantly larger proportion of non-suppressive T 
cell clones compared to FoxP3+Helios+ Tregs [39]. In 
line with our findings, other groups have also reported 
that effector cytokine secretion is mainly limited to 
the FoxP3+Helios− T cell subset, while FoxP3+Helios+ 
Tregs are non-cytokine producers, both in healthy and 
autoimmune disease settings [33, 39–42].
While it is recognized that two distinct subsets of 
Helios+ and Helios− Tregs exist within FoxP3+ Tregs, 
their role and function are still subject to debate and 
Helios is currently not regarded as a definitive marker 
to differentiate between pTregs and tTregs [32]. Very 
recently, in a Helios reporter mice, it was shown that 
Helios+ Tregs have superior ability than Helios− Tregs 
to suppress T-cell proliferation and cytokine production 
[29]. Our findings suggest that Helios defines a more 
suppressive Treg subset. This must however be confirmed 
in further mechanistic assays. As suggested earlier, 
FoxP3+Helios− Tregs might simply contain a mixture of 
non-suppressive and suppressive T cells rather than being 
intrinsically less suppressive than FoxP3+Helios+ Tregs. 
Indeed, human Helios+ and Helios− Tregs have previously 
been reported to exhibit a similar suppressive capacity 
although Helios− secreted greater levels of IFN-γ [32]. 
The different rates of proliferation reported in our study 
must also be interpreted carefully; although Tregs show 
an anergic phenotype in vitro, they proliferate at a much 
higher rate in vivo [43].
The FoxP3−Helios+ T cell population did not secrete 
significant levels of IL-10, IL-2 or IFN-γ and showed a 
proliferative capacity comparable to that of FoxP3+Helios+ 
Tregs. We can speculate that these might be TGF-β-
dependent Th3 cells. Expression of GARP and LAP, as 
surrogate markers for TGF-β, on these non-cytokine 
secreting T cells could further support the case for Th3 
cells being present. Helios has also been reported to be 
up-regulated in Th2 and follicular T helper cells (Tfh) 
independently of FoxP3 [44]. Further studies investigating 
the cytokine secretion profile of GARP/LAP expressing 
T cells with FoxP3 and Helios are required.
In accordance with other reports identifying 
GARP+LAP+ Tregs as highly immunosuppressive 
Tregs, we found that GARP+LAP+ cells secrete IL-10 
but not IFN-γ. A distinct GARPhighLAPhigh subset with 
over 90% of cells secreting IL-10 was also identified 
(Figure 3C). We noticed that following TCR activation, 
within FoxP3−Helios+ T cells, there is a subset expressing 
high level of LAP (Figure 2A & 2B). In contrast, 
FoxP3+Helios+ cells mainly increased GARP expression 
with LAP increased to a lower extent (Figure 2A). This 
could indicate that FoxP3 inhibits LAP expression or 
perhaps that, following activation, FoxP3+Helios+ Tregs 
release TGF-β from the cell surface. Indeed Tregs utilize 
TGF-β as a suppressive mechanism. One recent murine 
study reported that GARP expression was induced on 
FoxP3+ T cells following 24 hours of in vitro activation, 
while LAP expression was only induced after 48–72 h 
of activation [45]. A FoxP3−LAP+ Treg subset was also 
identified in humans [23]. These LAP+ Tregs secreted IL-
10, IFN-γ and TGF-β upon activation but were not studied 
for expression of GARP and Helios [23].
When interpreting these results, we should take 
into account the significant functional and phenotypic 
heterogeneity and plasticity that Tregs exhibit [12, 46, 
47]. Numerous tissue- and antigen-specific Treg subsets 
with distinct features exist, including follicular Tregs, 
‘ex-Tregs’, and IL-17-secreting Tregs. Immune regulation 
involves complex interplay and cross-talk between Treg 
subsets, Teff, DCs and other immune cells. Identification 
of highly suppressive individual Treg subsets is 
important. However, these subsets should be considered 
in the overall context of physiological or pathological 
immune functioning. Impact of Treg subsets on clinical 
outcomes can vary considerably [5, 48]. For example, 
immunotherapies enhanced Helios expression in CD4+ 
Tregs in the responder group of rheumatoid arthritis 
patients [49]. In contrast, in SLE patients, levels of 
Helios+ Tregs were significantly increased and correlated 
positively with SLE disease activity [41, 42].
Therapeutic modalities for treating autoimmune 
diseases, allergies and graft rejection should be designed to 
induce and/or expand the most suppressive Treg subsets. Our 
work suggests these might be the FoxP3+Helios+GARP+LAP+ 
Tregs. Recent work on a method for generating human 
allo-antigen specific Tregs was able to induce large-scale 
generation of suppressive Tregs all of which expressed 
FoxP3, Helios, GARP and LAP [50]. On the other hand, 
when treating cancers and infectious diseases, therapeutic 
modalities should avoid the generation and/or expansion of 
FoxP3+Helios+ Tregs to avoid compromising anti-tumor or 
anti-microbial immune responses.
Further investigations into levels and functions of 
FoxP3+/−Helios+/− T cell subsets as well as correlations 
with clinical outcomes in different disease settings should 
provide important insights for understanding the nature 
and role of these subsets. Utilizing GARP and LAP as 
cell surface markers for identifying highly suppressive 
FoxP3+Helios+ Tregs may enable effective isolation of 
highly suppressive Treg subsets, in the activated setting, 
both for therapeutic manipulation and further downstream 
investigations into Treg biology and diversity.
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MATERIALS AND METHODS
Cell isolation and preparation
Whole blood samples were either collected from 
healthy donors or were obtained from UK National 
Blood Service. Ethical approvals were obtained prior 
to samples’ collection. Peripheral blood mononuclear 
cells (PBMCs) were isolated from whole blood using 
Ficoll-Hypaque (Sigma-Aldrich, UK) density gradient 
centrifugation. PBMCs were then frozen at 5–10 × 106 
cells/ml in cryovials in 1 ml of freezing media (50% FCS, 
40% RPMI-1640 and 10% DMSO) and stored in liquid 
nitrogen (LN) for later use. Trypan blue was used for 
PBMC viability testing and counting.
GARP and LAP expression on Treg 
subpopulations
PBMCs were thawed and suspended at 2 × 106 cells/
well in 2 ml complete medium [RPMI-1640 supplemented 
with L-glutamine 2 mM, 10% FCS, Streptomycin 100 μg/
ml and Penicillin 100 Units/ml] in a 24-well non-treated 
culture plate. PBMCs were either plated as non-activated 
in non-coated wells or activated in pre-coated wells with 
plate-bound 2 μg/ml anti-CD3 antibody (clone OKT3 
clone, eBioscience, Hatfield, UK) and 2 μg/ml anti-CD28 
antibody (CD28.2 clone, eBioscience). Plated cells were 
incubated for 18–20 hours in a humidified incubator at 
37°C 5% CO2. Cells were collected and blocked for FcR 
with IgG from human serum (Sigma-Aldrich, UK) and 
were then stained for extracellular markers using mouse 
anti-human CD4-PerCP-Cy5.5 (eBioscience), mouse 
anti-human CD3-APC-H7 (BD Biosciences, Oxford, 
UK), mouse anti-human GARP-APC (BD Biosciences), 
and mouse anti-human LAP-PE (BD Biosciences). For 
intracellular markers, cells were subsequently fixed, 
permeabilized and blocked using rat serum (eBiosceince) 
and mouse serum (Sigma-Aldrich) before staining with rat 
anti-human FoxP3-PE-Cy7 (PCH101 clone, eBioscience) 
and Armenian hamster anti-mouse/human Helios-FITC 
(22F6 clone, Biolegend, Cambridge, UK). Following two 
further permeabilization washes, cells were re-suspended 
in flow cytometry buffer. Fixation, permeabilization and 
flow cytometry buffers were all from eBioscience or 
BD Biosciences and prepared as per the manufacturer’s 
instructions. Flow cytometric data was acquired on 
a FACSVerse or FACSCanto II flow cytometers (BD 
Biosciences, USA). Data analysis was performed using 
BD FACSuite or FlowJo version x 10.0.7r2 software.
Cytokine release from different Treg 
subpopulations
Thawed PBMCs were plated in complete medium in 
a 24-well non-treated culture plate pre-coated with 2 μg/
ml anti-CD3 and 2 μg/ml anti-CD28. To investigate IFN-γ 
and IL-10 release from subpopulations expressing GARP/
LAP or not, cells were incubated for 24 hours at 37°C 5% 
CO2 and 1 μg/ml Golgi Plug (BD Biosciences) was added 
for the last 4 hours of activation. Cells were first stained 
for extracellular markers using mouse anti-human CD4-
PerCP-Cy5.5, mouse anti-human CD3-APC-H7, mouse 
anti-human GARP-APC, and mouse anti-human LAP-PE. 
For intracellular cytokines, cells were subsequently fixed, 
permeabilized and blocked using mouse serum before 
staining with anti-human IL-10-FITC (eBioscience) and 
mouse anti-human IFNγ-PE-Cy7 (BD Pharmingen, BD 
Biosciences, UK).
In another experimental panel to investigate 
IFN-γ and IL-10 release from different subpopulations 
expressing FoxP3/Helios or not, cells were activated for 
24 hours, with Golgi Plug added for the last 4 hours, 
then stained for extracellular markers using mouse anti-
human CD4-PerCP-Cy5.5 and mouse anti-human CD3-
APC-H7. For intracellular transcription factors/cytokines, 
cells were subsequently fixed, permeabilized and blocked 
using rat and mouse serum before staining with rat anti-
human FoxP3-PE (eBioscience) and Armenian hamster 
anti-mouse/human Helios-FITC, together with rat anti-
human IL-10-APC (BD Pharmingen) and mouse anti-
human IFNγ-PE-Cy7. To investigate IL-2 release, cells 
were activated for 6 hours, with Golgi Plug added for the 
last 4 hours, followed by staining with rat anti-human 
IL-2-PE-Cy7 (eBioscience) and flow cytometric and data 
analysis were performed as described above.
CFSE-based proliferation assays
Proliferation of different subsets was measured 
by carboxyfluorescein diacetate succinimidyl ester 
(CFSE)-based proliferation assays. Briefly, PBMCs were 
suspended at 1 × 106 cells/ml in pre-warmed 0.1% BSA in 
PBS and incubated with 0.25 μM CFSE/ml (eBioscience) 
for 10 minutes at 37°C, followed by a series of washes. 
CFSE-labeled cells were suspended in complete medium 
and were polyclonally stimulated with plate-bound 
2 μg/ml anti-CD3 and 2 μg/ml anti-CD28. Cells were 
incubated for 3 days in a humidified incubator at 37°C 
5% CO2. CFSE-labeled cells were then stained for surface 
markers using anti-CD3-APC-H7 and anti-CD4-PerCp-5.5 
antibodies, followed by intracellular staining using anti-
FoxP3-PE-Cy7 and anti-Helios-APC antibodies. In 
another experimental setting, CD25 expression in different 
FoxP3/Helios CD4+ T-cell subsets was determined using 
mouse anti-human CD25-APC-H7 (BD Biosciences). 
Proliferation and various marker expressions in different 
subsets were evaluated by flow cytometry.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 5.0 software (GraphPad Software, United States). 
Paired T test was used to test for differences within groups. 
Oncotarget20035www.impactjournals.com/oncotarget
P value ≤ 0.05 was considered statistically significant. The 
data are presented as means ± SEM.
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